Two studies published in recent weeks have demonstrated the effectiveness of hydroxychloroquine, a drug commonly used to treat malaria that has been discredited by the WHO and mainstream media as an effective treatment for the CCP (Chinese Communist Party) Virus also known as COVID-19.
A study in Italy, published in the European Journal of Internal Medicine, found that hydroxychloroquine reduces up to 30% of the risk of death for those hospitalized from the infection. The study was applied to 3,451 patients who were treated in 33 hospitals throughout Italy.
According to Augusto Di Castelnuovo, epidemiologist of the Department of Epidemiology and Prevention of Neuromed, “Patients treated with hydroxychloroquine had a 30% lower in-hospital mortality rate compared to those not receiving this treatment.”
The researchers relied on analysis of data on current and past illnesses, as well as therapies applied prior to infection and drugs administered in the hospital specifically for the treatment of the CCP Virus.
According to Licia Liacovello, director of the Department of Epidemiology and Prevention at Neuromed and professor of public health at the University of Insubria in Varese, while further observational studies and clinical trials are needed to assess the role of the drug, data from the CORIST ( COvid-19 RISk and Treatments) collaboration support the use of hydroxychloroquine.
“Our data was subjected to extremely rigorous statistical analysis, taking into account all the variables and possible confounding factors that could come into play. The drug efficacy was evaluated in various subgroups of patients,” explained Castelnuovo.
“The positive results of hydroxychloroquine treatment remained unchanged, especially in those patients showing a more evident inflammatory state at the moment of admission to hospital,” added Castelnuovo, as reported by EurekAlert.
Giovanny Gaetano, president of Neuromed recalled how in recent months the World Health Organization (WHO) recommended stopping the use of this drug based on an international study.
Another study published on the medRxiv website, focused on the analysis of 1,274 outpatients infected with SARS-CoV2 in New Jersey, implemented the prescription of hydroxychloroquine, finding that cases per hospitalization were reduced by up to 47%.
As indicated by The Blaze, because the study was conducted at the beginning of the pandemic when there were high numbers of symptomatic persons, researchers believe that their sample of more than 1,200 patients represents persons with relatively more advanced cases of COVID-19.
The study concluded that hydroxychloroquine can be effective even when administered early after a positive diagnosis of the CCP virus. The study also showed that the diagnosis of the people who received the drug did not detect any negative side effects.